It is becoming more and more apparent that microvascular dysfunction (disease of small blood vessels in the body) is responsible for morbidity and mortality in many different diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, development of ischaemic heart disease in the absence of obstructive coronary disease. Microvascular dysfunction often goes hand in hand with chronic inflammatory condition. However, nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of adverse cardiovascular events. Therefore, there is a need for medications that can have anti-inflammatory effect, as well as, vasodilatory effect or at least not cause any adverse effect on the vascular system. Gesynta is pioneering the development of a first-in-class molecule that has combined anti-inflammatory, anti-thrombotic and vasodilatory effect through a novel pathway. As a first indication Gesynta is focusing on Systemic sclerosis (SSc) but the molecule has much broader potential.
We invested in Gesynta because there is a clear unmet medical need in the space as there are no drugs approved in the US and the two approved drugs in the EU have severe side effects.